14 Sep

Sarepta Therapeutics Has Returned 169.97% Year-to-Date

WRITTEN BY Margaret Patrick

Revenue and earnings trends

Sarepta Therapeutics (SRPT) has returned 169.97% YTD (year-to-date). In the second quarter, it reported EPS of -$0.43, surpassing the consensus estimate by $0.46. EXONDYS 51 sales were $73.5 million in the quarter, which is a YoY (year-over-year) rise of 110%. EXONDYS sales were $138 million in the first half of 2018. The company expects to report $295 million–$305 million in sales of EXONDYS 51 in 2018.

Sarepta Therapeutics Has Returned 169.97% Year-to-Date

Analyst recommendations for Sarepta Therapeutics

The consensus recommendation for Sarepta Therapeutics over the next 12 months is a “buy.” Of the 21 analysts covering the stock in September, seven have recommended a “strong buy,” 13 have recommended a “buy,” and one has recommended a “hold.”

Wall Street analysts have projected a 12-month consensus target price of $188.58, which is a 25.54% rise over its closing price on September 13.

Growth drivers

By the end of 2018, Sarepta Therapeutics plans to submit a rolling NDA (New Drug Application) to the FDA for golodirsen, an investigational phosphorodiamidate Morpholino oligomer (or PMO) therapy, in Duchenne muscular dystrophy (or DMD) due to deletions in the DMD gene related to exon 53 skipping. The company has estimated that 8% of DMD patients have exon 53 amenable mutations in their DMD gene. The company expects an FDA decision in 2019.

Sarepta Therapeutics is studying another investigational PMO therapy, casimersen, in the Phase 3 ESSENCE trial for DMD patients with DMD gene mutations amenable to exon 45 skipping. The company has conducted a Type C meeting with the FDA related to this trial. These efforts may accelerate the FDA approval process for casimersen.

While 13% of the DMD patient population is currently eligible for treatment with EXONDYS 51, regulatory approvals for casimersen and golodirsen are expected to expand the addressable market opportunity for Sarepta Therapeutics to 30% of the DMD patient population.

Next, let’s look at the growth trends for Regenxbio.

Latest articles

US crude oil production has more than doubled since 2009 and grew by 1.1% over the last year. Currently, there are 133 operable refineries in the US.

The cannabis industry is fighting against the ongoing US-China trade war and recessionary worries, which have hurt valuations across the global market.

Higher revenues, increased ticket prices, and lower fuel costs are likely to drive American Airlines' Q3 earnings higher despite its Boeing MAX woes.

HEXO plans to report its Q4 earnings before the market opens on October 24. October has been tough for Hexo, with its stock falling 31.2% as of October 18.

Today, Advanced Micro Devices (AMD) rose 4% to over $32, making it one of the top Nasdaq gainers. Morgan Stanley raised its price target for AMD stock.

Early in 2019, President Donald Trump warned that China could overtake the US as a global power. He vowed that this would not happen under his leadership.